[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"DJ Orthopedics de Mexico S.A. de C.V.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":105},{"warningLetters":4,"total":104},[5,31,51,68,86],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},3456,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-03-16T13:20:00Z\">03\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-11T05:00:00Z\">03\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falbek-de-mexico-sa-de-cv-609202-03112021\">Albek de Mexico S.A. de C.V.\u003C\u002Fa>","Center for Drug Evaluation and Research","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. José Manuel Beltrán Mendoza\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Albek de Mexico S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Oriente 4 No. 11\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nuevo Parque Industrial\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>76809\u003C\u002Fspan> \u003Cspan>San Juan del Río\u003C\u002Fspan>, \u003Cspan>Qro.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-35\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nMarch 11, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Beltrán Mendoza:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER. This drug product was declared to be manufactured at your facility, Albek de Mexico S.A. de C.V., FEI 3009115034, at Oriente 4 No. 11, Nuevo Parque Industrial, San Juan del Río, Queretaro, Mexico. Following an attempt to import NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of batches of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER, declared to be manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of batches of this product detained at the border found that one batch contained an average of 39% ethanol and an average of 27% methanol v\u002Fv. A second batch contained an average of 38% ethanol and an average of 27% methanol v\u002Fv. A third batch contained an average of 55% ethanol and an average of 10% methanol v\u002Fv. A fourth batch contained on average of 37% ethanol and an average of 29% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>On July 27, 2020, FDA held a teleconference with you and Registrar Corporation, your registered U.S. Agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On July 28, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug products at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On July 31, 2020, you issued a voluntary nationwide recall of NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Falbek-de-mexico-sa-de-cv-issues-voluntary-nationwide-recall-all-hand-sanitizers-due-potential#:~:text=SAN%20JUAN%20del%20RIO%20QUERETARO,2019%20and%20June%2028%2C%202020\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Falbek-de-mexico-sa-de-cv-issues-voluntary-nationwide-recall-all-hand-sanitizers-due-potential#:~:text=SAN%20JUAN%20del%20RIO%20QUERETARO,2019%20and%20June%2028%2C%202020\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation into how the drug product described above, which was declared to be manufactured at your facility and which was labeled as containing ethanol, was substituted in part or in whole with methanol.\u003C\u002Fli>\n\t\u003Cli>A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003C\u002Fli>\n\t\u003Cli>A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fli>\n\t\u003Cli>Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fli>\n\t\u003Cli>Provide your test methods for testing raw materials and your hand sanitizer drug products. If you intend to accept any results from your supplier’s Certificate of Analysis instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. We note that identity testing is required for every lot of components regardless of supplier test result validation. Your policy should include a requirement that you test every lot of ethanol you receive for methanol content using the United States Pharmacopeia (USP) method in a CGMP compliant laboratory.\u003C\u002Fli>\n\t\u003Cli>Discuss the corrective action to test all of your drug products prior to release for strength and identity of the active ingredient.\u003C\u002Fli>\n\t\u003Cli>In correspondence received from your customer’s outside counsel it was stated your firm conducted raw material and finished product testing and confirmed the purity of the ethanol used in hand sanitizer lots. FDA test results demonstrate substitution of methanol for ethanol in your hand sanitizer drug products and call into question the purity of the ethanol used to manufacture them. FDA questions the validity of test results generated by your facility or by others on your behalf. Provide a complete, comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The substitution and contamination with methanol in a drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic hand rub.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Drug Facts . . . Uses ·\u003C\u002Fstrong> To decrease bacteria on the skin when water, soap &amp; towel are not available.”\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Directions\u003C\u002Fstrong> . . . Apply enough product to wet hands. Rub hands together until dry. Supervise children in use of this product.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of this product detained at the border demonstrated that NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER contain ethyl alcohol in a concentration that is less than the 70% v\u002Fv stated on its product label and less than the amount of ethyl alcohol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses also demonstrated that batches of NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER, is misbranded under sections 502(j), (a), (e), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), and (ee). It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is labeled to contain ethyl alcohol 70% v\u002Fv. However, FDA laboratory analysis of batches of this product demonstrates that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of this drug product to list methyl alcohol (methanol) as an ingredient on its label causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 4, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3009115034 and ATTN: Tamara Rosbury.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nDavid Lennarz\u003Cbr>\nRegistrar Corporation\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, VA, 23666\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative testing results detailed above that demonstrate the substitution of hand sanitizer products declared as manufactured at your facility, a review of the purported formulations on the drug products’ labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem>. Because NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. José Manuel Beltrán Mendoza\n\nRecipient Title\n\nCEO\u002FPresident\n\nAlbek de Mexico S.A. de C.V.\n\nOriente 4 No. 11\n\nNuevo Parque Industrial\n\n76809 San Juan del Río, Qro.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWarning Letter 320-21-35\n\nMarch 11, 2021\n\nDear Mr. Beltrán Mendoza:\n\nYour firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER. This drug product was declared to be manufactured at your facility, Albek de Mexico S.A. de C.V., FEI 3009115034, at Oriente 4 No. 11, Nuevo Parque Industrial, San Juan del Río, Queretaro, Mexico. Following an attempt to import NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of batches of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nNEXT ADVANCED ANTIBACTERIAL HAND SANITIZER, declared to be manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of batches of this product detained at the border found that one batch contained an average of 39% ethanol and an average of 27% methanol v\u002Fv. A second batch contained an average of 38% ethanol and an average of 27% methanol v\u002Fv. A third batch contained an average of 55% ethanol and an average of 10% methanol v\u002Fv. A fourth batch contained on average of 37% ethanol and an average of 29% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nOn July 27, 2020, FDA held a teleconference with you and Registrar Corporation, your registered U.S. Agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On July 28, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug products at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nOn July 31, 2020, you issued a voluntary nationwide recall of NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Falbek-de-mexico-sa-de-cv-issues-voluntary-nationwide-recall-all-hand-sanitizers-due-potential#:~:text=SAN%20JUAN%20del%20RIO%20QUERETARO,2019%20and%20June%2028%2C%202020.\n\nIn response to this letter provide the following:\n\nA detailed investigation into how the drug product described above, which was declared to be manufactured at your facility and which was labeled as containing ethanol, was substituted in part or in whole with methanol.\n\nA list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\nA list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\nCopies of the complete batch records for all batches distributed to the U.S.\n\nProvide your test methods for testing raw materials and your hand sanitizer drug products. If you intend to accept any results from your supplier’s Certificate of Analysis instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. We note that identity testing is required for every lot of components regardless of supplier test result validation. Your policy should include a requirement that you test every lot of ethanol you receive for methanol content using the United States Pharmacopeia (USP) method in a CGMP compliant laboratory.\n\nDiscuss the corrective action to test all of your drug products prior to release for strength and identity of the active ingredient.\n\nIn correspondence received from your customer’s outside counsel it was stated your firm conducted raw material and finished product testing and confirmed the purity of the ethanol used in hand sanitizer lots. FDA test results demonstrate substitution of methanol for ethanol in your hand sanitizer drug products and call into question the purity of the ethanol used to manufacture them. FDA questions the validity of test results generated by your facility or by others on your behalf. Provide a complete, comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nThe substitution and contamination with methanol in a drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.1\n\nUnapproved New Drug and Misbranding Violations\n\nNEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic hand rub.\n\nExamples of claims observed on the NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Drug Facts . . . Uses · To decrease bacteria on the skin when water, soap & towel are not available.”\n\n“Directions . . . Apply enough product to wet hands. Rub hands together until dry. Supervise children in use of this product.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of this product detained at the border demonstrated that NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER contain ethyl alcohol in a concentration that is less than the 70% v\u002Fv stated on its product label and less than the amount of ethyl alcohol described in the 1994 TFM.2 Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.3\n\nFDA laboratory analyses also demonstrated that batches of NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.4\n\nAdditionally, this methanol-containing drug product, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER, is misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), and (ee). It is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is labeled to contain ethyl alcohol 70% v\u002Fv. However, FDA laboratory analysis of batches of this product demonstrates that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of this drug product to list methyl alcohol (methanol) as an ingredient on its label causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 4, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3009115034 and ATTN: Tamara Rosbury.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\ncc:\n\nRegistered U.S. Agent\n\nDavid Lennarz\n\nRegistrar Corporation\n\n144 Research Drive\n\nHampton, VA, 23666\n\n_________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative testing results detailed above that demonstrate the substitution of hand sanitizer products declared as manufactured at your facility, a review of the purported formulations on the drug products’ labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because NEXT ADVANCED ANTIBACTERIAL HAND SANITIZER is not consistent with the formulations in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n4 An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Albek de Mexico S.A. de C.V.","albek-de-mexico-sa-de-cv-609202-03112021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falbek-de-mexico-sa-de-cv-609202-03112021","2026-10-26T08:07:52.082237+00:00","Warning Letter","Issued","2021-03-16","609202","Drugs","Mr. José Manuel Beltrán Mendoza","2026-08-20T03:16:15.6+00:00","VIA UPS","2021-03-11",{"id":32,"raw":33,"subject":12,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},3562,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-02-02T14:20:00Z\">02\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-26T05:00:00Z\">01\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrupo-yacana-mexico-sas-de-cv-609824-01262021\">Grupo Yacana Mexico, S.A.S. de C.V.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Sofia Corona Gonzalez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Laboratory and Production Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Grupo Yacana Mexico, S.A.S. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Av. Alfonso Reyes No. 714\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Country la Silla Sector 4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>67173\u003C\u002Fspan> \u003Cspan>Guadalupe\u003C\u002Fspan>, \u003Cspan>N.L.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-20\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 26, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Sofia Corona Gonzalez:\u003C\u002Fp>\n\n\u003Cp>Your firm recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers) labeled as YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub. These drug products were labeled as manufactured at your facility, Grupo Yacana Mexico, S.A.S. de C.V., FEI 3015123543, at Av. Alfonso Reyes No. 714, Guadalupe (Country la Silla Sector 4), Nuevo Leon, Mexico. Following an attempt to import YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub into the United States, they were detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of batches of these products detained at the border demonstrate that the YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug products, labeled as manufactured at your facility, are adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of a batch of YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug product, labeled as manufactured at your facility, is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or represents to possess.\u003C\u002Fp>\n\n\u003Cp>These products are also adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the substitution and subpotency demonstrate that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003Cbr>\n\u003Cbr>\nIn addition, your YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and are misbranded under sections (a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee). YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is further misbranded under sections 502(j) and (e) of the FD&amp;C Act, 21 U.S.C. 352(j), and (e). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations: Substitution\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of one batch of this product detained at the border found that the drug product contained on average 0.04% ethanol v\u002Fv and an average of 63% methanol v\u002Fv. FDA laboratory testing of another batch of this product detained at the border found on average 3.6% ethanol v\u002Fv and an average of 59% methanol v\u002Fv. FDA laboratory testing of a third batch of this product detained at the border found on average 0.6% ethanol v\u002Fv and an average of 49% methanol v\u002Fv.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidently ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>Additionally, YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% (v\u002Fv) of the active ingredient Isopropyl Alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained on average of 53% ethanol v\u002Fv and 0% (v\u002Fv) IPA.\u003C\u002Fp>\n\n\u003Cp>Therefore, these hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient of ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations: Subpotency\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% (v\u002Fv) of the active ingredient isopropyl alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that it contained 61% IPA (v\u002Fv) and 0.7% ethanol (v\u002Fv). This hand sanitizer drug product is adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of IPA is present at levels in the product lower than that which is declared on its labeling. CDC recommends\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 70% IPA. This is the minimum active ingredient concentration of IPA specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>On August 12, 2020, FDA held a teleconference with you and Pragmatic Compliance LLC, your registered U.S. Agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. FDA notified the public of the subpotency and methanol contamination of your hand sanitizer drug products at the following webpage: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On August 18, 2020, you issued a voluntary nationwide recall of all your hand sanitizer drug products due to the presence of undeclared methanol (Wood Alcohol) and subpotent ethanol, as noted on the following webpage:\u003Cbr>\n\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fgrupo-yacana-mexico-sas-de-cv-issues-voluntary-nationwide-recall-all-lots-yacana-hand-sanitizer-due\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fgrupo-yacana-mexico-sas-de-cv-issues-voluntary-nationwide-recall-all-lots-yacana-hand-sanitizer-due\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003Cbr>\n• A detailed investigation into how the drug products described above, which were labeled as manufactured at your facility and which were labeled as containing ethanol or IPA, were substituted in part or in whole with methanol or ethanol, respectively.\u003Cbr>\n• A detailed investigation into how the hand sanitizer drug products described above, which were labeled as containing 70% IPA, in fact contained an average of 61% IPA (v\u002Fv).\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the supplier’s names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fp>\n\n\u003Cp>The substitution and contamination with methanol in hand sanitizer drug products labeled as manufactured in your facility, as well as the subpotency of hand sanitizer products labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer antiseptic rubs.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub product labels that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “Drug Facts…Uses…Hand Sanitizer to help reduce bacteria that potentially can cause disease…”\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “Directions…Place enough product to cover all surfaces, rub hand together until dry…”\u003C\u002Fp>\n\n\u003Cp>These topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for these products, as further described below). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for either of these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>Over the course of these rulemakings, benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol were classified as Category III for use as active ingredients in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 -- and that were not classified as Category II for safety or effectiveness -- are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub purportedly contains the active ingredient ethyl alcohol (ethanol) 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of these products detained at the border demonstrated that YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub contains ethanol in a concentration that is less than the 70% stated on its product label and far less than the amount of ethanol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform to the TFM or applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses of batches of this product detained at the border revealed that batches of YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub contain significant concentrations of the undeclared ingredient, methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the TFM, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>According to its label, YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub purportedly contains the active ingredient isopropyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses revealed that batches of these products detained at the border contain isopropyl alcohol, which is less than the 70% stated on its product label and less than the amount of isopropyl alcohol described in the 1994 TFM. Furthermore, the analyses revealed that the product contained concentrations of an undeclared ingredient, ethanol. Ethanol as a sole active ingredient is permitted for use as a consumer or health care personnel antiseptic hand rub. However, even if ethanol was intended to be the only active ingredient for the product, the concentrations of the undeclared ingredient is below the concentration allowed under the TFM. Such a product does not conform to the TFM or applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>Additionally, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under sections 502(j), (a), (e), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), and (e). YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee).\u003C\u002Fp>\n\n\u003Cp>YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death. The failure of this product to list methanol as an ingredient on its label also causes YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because their labeling is false or misleading. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” As noted above, of YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is labeled to contain ethanol 70% v\u002Fv. However, FDA laboratory analyses of batches of this product demonstrate that the product contains a concentration of ethanol that is far less than the 70% stated on the product label and instead contains significant concentrations of methanol, an ingredient that is not declared on the product labels. Similarly, as noted above, Yacana Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub is labeled to contain isopropyl alcohol 70% v\u002Fv. However, FDA laboratory analyses of batches of this product demonstrate that the product contains isopropyl alcohol, which is less than the 70% stated on its product label and contains ethanol even though the product label does not include ethanol as an ingredient. Thus, the misleading representation of the concentration of active ingredient ethanol and the failure of the product label to disclose the presence of the methanol in the product, causes YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>Lastly, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and they are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 20, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3015123543 and ATTN: Philip Kreiter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nMr. Jerry Doane\u003Cbr>\nPragmatic Compliance LLC\u003Cbr>\n15815 SW 11th Court Rd.\u003Cbr>\nOcala, FL 34473\u003Cbr>\nUSA\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.cdc.gov\u002Fcoronavirus\u002F2019-ncov\u002Fhcp\u002Fhand-hygiene.html\">https:\u002F\u002Fwww.cdc.gov\u002Fcoronavirus\u002F2019-ncov\u002Fhcp\u002Fhand-hygiene.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we&nbsp;do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution and contamination of methanol in hand sanitizer products labeled as manufactured at your facility, as well as the subpotency of hand sanitizer products labeled as manufactured at your facility, a review of the drug products’ labeling further indicate that these products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Sofia Corona Gonzalez\n\nRecipient Title\n\nLaboratory and Production Manager\n\nGrupo Yacana Mexico, S.A.S. de C.V.\n\nAv. Alfonso Reyes No. 714\n\nCountry la Silla Sector 4\n\n67173 Guadalupe, N.L.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-20\n\nJanuary 26, 2021\n\nDear Ms. Sofia Corona Gonzalez:\n\nYour firm recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers) labeled as YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub. These drug products were labeled as manufactured at your facility, Grupo Yacana Mexico, S.A.S. de C.V., FEI 3015123543, at Av. Alfonso Reyes No. 714, Guadalupe (Country la Silla Sector 4), Nuevo Leon, Mexico. Following an attempt to import YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub into the United States, they were detained and refused admission at the border.\n\nThe results of FDA laboratory testing of batches of these products detained at the border demonstrate that the YACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug products, labeled as manufactured at your facility, are adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor.\n\nThe results of FDA laboratory testing of a batch of YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug product, labeled as manufactured at your facility, is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or represents to possess.\n\nThese products are also adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the substitution and subpotency demonstrate that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, your YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and are misbranded under sections (a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee). YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is further misbranded under sections 502(j) and (e) of the FD&C Act, 21 U.S.C. 352(j), and (e). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a).\n\nAdulteration Violations: Substitution\n\nYACANA Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of one batch of this product detained at the border found that the drug product contained on average 0.04% ethanol v\u002Fv and an average of 63% methanol v\u002Fv. FDA laboratory testing of another batch of this product detained at the border found on average 3.6% ethanol v\u002Fv and an average of 59% methanol v\u002Fv. FDA laboratory testing of a third batch of this product detained at the border found on average 0.6% ethanol v\u002Fv and an average of 49% methanol v\u002Fv.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidently ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nAdditionally, YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% (v\u002Fv) of the active ingredient Isopropyl Alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained on average of 53% ethanol v\u002Fv and 0% (v\u002Fv) IPA.\n\nTherefore, these hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient of ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nAdulteration Violations: Subpotency\n\nYACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub, labeled as manufactured at your facility, is labeled to contain 70% (v\u002Fv) of the active ingredient isopropyl alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that it contained 61% IPA (v\u002Fv) and 0.7% ethanol (v\u002Fv). This hand sanitizer drug product is adulterated under section 501(c) of the FD&C Act in that the active ingredient of IPA is present at levels in the product lower than that which is declared on its labeling. CDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 70% IPA. This is the minimum active ingredient concentration of IPA specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOn August 12, 2020, FDA held a teleconference with you and Pragmatic Compliance LLC, your registered U.S. Agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. FDA notified the public of the subpotency and methanol contamination of your hand sanitizer drug products at the following webpage: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nOn August 18, 2020, you issued a voluntary nationwide recall of all your hand sanitizer drug products due to the presence of undeclared methanol (Wood Alcohol) and subpotent ethanol, as noted on the following webpage:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fgrupo-yacana-mexico-sas-de-cv-issues-voluntary-nationwide-recall-all-lots-yacana-hand-sanitizer-due\n\nIn response to this letter provide the following:\n\n• A detailed investigation into how the drug products described above, which were labeled as manufactured at your facility and which were labeled as containing ethanol or IPA, were substituted in part or in whole with methanol or ethanol, respectively.\n\n• A detailed investigation into how the hand sanitizer drug products described above, which were labeled as containing 70% IPA, in fact contained an average of 61% IPA (v\u002Fv).\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the supplier’s names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\nThe substitution and contamination with methanol in hand sanitizer drug products labeled as manufactured in your facility, as well as the subpotency of hand sanitizer products labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nUnapproved New Drug and Misbranding Violations\n\nYACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer antiseptic rubs.\n\nExamples of claims observed on the YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub product labels that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“Drug Facts…Uses…Hand Sanitizer to help reduce bacteria that potentially can cause disease…”\n\n“Directions…Place enough product to cover all surfaces, rub hand together until dry…”\n\nThese topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for these products, as further described below). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for either of these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub drug products are GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOver the course of these rulemakings, benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol were classified as Category III for use as active ingredients in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Section 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 -- and that were not classified as Category II for safety or effectiveness -- are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub purportedly contains the active ingredient ethyl alcohol (ethanol) 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses of batches of these products detained at the border demonstrated that YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub contains ethanol in a concentration that is less than the 70% stated on its product label and far less than the amount of ethanol described in the 1994 TFM.3 Such a product does not conform to the TFM or applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.4\n\nFDA laboratory analyses of batches of this product detained at the border revealed that batches of YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub contain significant concentrations of the undeclared ingredient, methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the TFM, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.5\n\nAccording to its label, YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub purportedly contains the active ingredient isopropyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analyses revealed that batches of these products detained at the border contain isopropyl alcohol, which is less than the 70% stated on its product label and less than the amount of isopropyl alcohol described in the 1994 TFM. Furthermore, the analyses revealed that the product contained concentrations of an undeclared ingredient, ethanol. Ethanol as a sole active ingredient is permitted for use as a consumer or health care personnel antiseptic hand rub. However, even if ethanol was intended to be the only active ingredient for the product, the concentrations of the undeclared ingredient is below the concentration allowed under the TFM. Such a product does not conform to the TFM or applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\n\nAdditionally, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under sections 502(j), (a), (e), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), and (e). YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee).\n\nYACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death. The failure of this product to list methanol as an ingredient on its label also causes YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A).\n\nYACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because their labeling is false or misleading. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” As noted above, of YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub is labeled to contain ethanol 70% v\u002Fv. However, FDA laboratory analyses of batches of this product demonstrate that the product contains a concentration of ethanol that is far less than the 70% stated on the product label and instead contains significant concentrations of methanol, an ingredient that is not declared on the product labels. Similarly, as noted above, Yacana Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub is labeled to contain isopropyl alcohol 70% v\u002Fv. However, FDA laboratory analyses of batches of this product demonstrate that the product contains isopropyl alcohol, which is less than the 70% stated on its product label and contains ethanol even though the product label does not include ethanol as an ingredient. Thus, the misleading representation of the concentration of active ingredient ethanol and the failure of the product label to disclose the presence of the methanol in the product, causes YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nLastly, YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and they are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 20, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\n\nIdentify your response with FEI 3015123543 and ATTN: Philip Kreiter.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent\n\nMr. Jerry Doane\n\nPragmatic Compliance LLC\n\n15815 SW 11th Court Rd.\n\nOcala, FL 34473\n\nUSA\n\n_______________________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fcoronavirus\u002F2019-ncov\u002Fhcp\u002Fhand-hygiene.html\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution and contamination of methanol in hand sanitizer products labeled as manufactured at your facility, as well as the subpotency of hand sanitizer products labeled as manufactured at your facility, a review of the drug products’ labeling further indicate that these products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n3 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n4 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because YACANA Antiseptic 70% Topical Solution Antiseptic Hand Rub and YACANA Isopropyl Alcohol Antiseptic 70% Topical Solution Antiseptic Hand Rub are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n5 An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Grupo Yacana Mexico, S.A.S. de C.V.","grupo-yacana-mexico-sas-de-cv-609824-01262021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrupo-yacana-mexico-sas-de-cv-609824-01262021","2026-10-26T08:08:50.901888+00:00","2021-02-02","609824","Ms. Sofia Corona Gonzalez","2026-08-20T03:25:10.775+00:00","2021-01-26",{"id":52,"raw":53,"subject":12,"body_html":57,"body_text":58,"firm_name":59,"letter_id":60,"created_at":43,"fei_number":19,"letter_url":61,"updated_at":62,"action_type":22,"case_status":23,"posted_date":63,"marcs_cms_no":64,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":65,"body_fetched_at":66,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":67,"medical_device_id":19,"response_letter_date":19},3553,[54,55,56,37,12,13,13,13],"\u003Ctime datetime=\"2021-02-09T14:20:00Z\">02\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-28T05:00:00Z\">01\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsimex-logistics-sa-de-cv-610529-01282021\">Simex Logistics S.A. de C.V.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jose Ambrosio Rodriguez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Simex Logistics S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Salvatierra No. 101 Fracc. El Puente\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>38060\u003C\u002Fspan> \u003Cspan>Celaya\u003C\u002Fspan>, \u003Cspan>Gto.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-21\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nJanuary 28, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Rodriguez:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The United States Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as HEALTH &amp; HAND GEL HAND SANITIZER. This drug product was manufactured at your facility, Simex logistics S.A. de C.V, FEI 3016774460, at Salvatierra No. 101 Fracc. El Puente, Celaya Guanajuato, Mexico 38060. Following an attempt to import this drug product into the United States, HEALTH &amp; HAND GEL HAND SANITIZER was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch (lot # 0720) of this product detained at the border demonstrate that HEALTH &amp; HAND GEL HAND SANITIZER drug product manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency and documents provided demonstrate that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, your HEALTH &amp; HAND GEL HAND SANITIZER drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a) and is misbranded under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>HEALTH &amp; HAND GEL HAND SANITIZER, manufactured at your facility, is labeled to contain 70% of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that this product contained an average of 51% ethanol volume\u002Fvolume (v\u002Fv). This hand sanitizer drug product is adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its labeling.\u003C\u002Fp>\n\n\u003Cp>CDC recommends\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>On October 7, 2020, FDA held a teleconference with you and your registered U.S. Agent. We requested additional information concerning your CGMP operations, including test methods for your finished drug product. In your response, you provided information on the gel formulation used for the drug products you produce, as well as, third party testing conducted on 10 of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;lots offered for importation. The third party testing conducted on “lot 0720”, the same as that tested by FDA, identified variability in the formulation. Specifically, the first sample from the upper layers of the bottle demonstrated subpotency (54%) and upon additional mixing of the sampe bottle you obtained a result of 68%. Your gel formulation does not appear to have uniform character and quality. Furthermore, you acknowledged that Simex released at least two of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots to the U.S. market without performing finished product testing, a violation of 21 CFR 211.165.\u003C\u002Fp>\n\n\u003Cp>In addition to the third party testing results, you offered details on the in-house testing that you are now using to test your drug products. The method of in-house testing uses a refractometer device that is unsuitable for the testing of finished hand sanitizers that contain materials other than ethanol and water in their matrix. Furthermore, you state that due to the “antiseptic nature of the product” there is no testing performed for objectionable microbiological contamination. Failure to adequately test prior to release or assure that the drug products have the identity, strength, quality and purity they purport or are represented to possess are violations of CGMP requirements. See 21 CFR 211.165 and 211.100.\u003C\u002Fp>\n\n\u003Cp>Ultimately, you committed to recall all hand sanitizer drug products manufactured by your firm within expiration. You issued a voluntary recall on November 25, 2020. On November 10, 2020, FDA notified the public of the subpotency of your hand sanitizer drugs products at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003Cbr>\n• Your plans to reformulate your drug product.\u003Cbr>\n• A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing including both production and packaging operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003Cbr>\n• A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003Cbr>\n• A list of appropriate chemical and microbial test methods and specifications used to analyze each lot of your components and drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fp>\n\n\u003Cp>The subpotency of active ingredient ethanol in this drug product declared as manufactured at your facility and the documents you provided demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the Act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>HEALTH &amp; HAND GEL HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the HEALTH &amp; HAND GEL HAND SANITIZER product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“HAND SANITIZER . . . Drug Facts . . . Purpose . . . Antimicrobial . . . Use(s) . . . Helps reduce bacteria on the skin that could cause diseases . . . \u003Cstrong>Directions\u003C\u002Fstrong> ∙ Place enough product in the palm of your hands to thoroughly cover your hands. ∙ Rub hands together briskly until product is completely absorbed and hands are dry.” (product label)\u003Cbr>\n\u003Cbr>\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your HEALTH &amp; HAND GEL HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, HEALTH &amp; HAND GEL HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act, as added by the CARES Act, for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, HEALTH &amp; HAND GEL HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 70%. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that HEALTH &amp; HAND GEL HAND SANITIZER contains ethanol in a concentration that is less than the 70% stated on its product label and less than the amount of ethanol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this drug product, HEALTH &amp; HAND GEL HAND SANITIZER, is misbranded under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee).\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, HEALTH &amp; HAND GEL HAND SANITIZER is labeled to contain ethyl alcohol 70%. However, FDA laboratory analyses of a batch of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label. Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol) in the product causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because HEALTH &amp; HAND GEL HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on November 17, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practice within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016774460 and ATTN: Tamara Ely.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nAldo Martinez\u003Cbr>\n1600 University Blvd\u003Cbr>\nBrownsville, Texas 78520\u003Cbr>\ncontrol@regulab.us\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\">https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of ethanol in hand sanitizer products manufactured at your facility, a review of your drug product labeling further indicates that the product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because HEALTH &amp; HAND GEL HAND SANITIZER is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jose Ambrosio Rodriguez\n\nRecipient Title\n\nCEO\n\nSimex Logistics S.A. de C.V.\n\nSalvatierra No. 101 Fracc. El Puente\n\n38060 Celaya, Gto.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-21\n\nJanuary 28, 2021\n\nDear Mr. Rodriguez:\n\nYour firm is registered as a human drug manufacturer. The United States Food and Drug Administration (FDA) conducted testing of a consumer antiseptic rub drug product (also referred to as a consumer hand sanitizer), labeled as HEALTH & HAND GEL HAND SANITIZER. This drug product was manufactured at your facility, Simex logistics S.A. de C.V, FEI 3016774460, at Salvatierra No. 101 Fracc. El Puente, Celaya Guanajuato, Mexico 38060. Following an attempt to import this drug product into the United States, HEALTH & HAND GEL HAND SANITIZER was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch (lot # 0720) of this product detained at the border demonstrate that HEALTH & HAND GEL HAND SANITIZER drug product manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)), in that the subpotency and documents provided demonstrate that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, your HEALTH & HAND GEL HAND SANITIZER drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a) and is misbranded under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nHEALTH & HAND GEL HAND SANITIZER, manufactured at your facility, is labeled to contain 70% of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that this product contained an average of 51% ethanol volume\u002Fvolume (v\u002Fv). This hand sanitizer drug product is adulterated under section 501(c) of the FD&C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its labeling.\n\nCDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOn October 7, 2020, FDA held a teleconference with you and your registered U.S. Agent. We requested additional information concerning your CGMP operations, including test methods for your finished drug product. In your response, you provided information on the gel formulation used for the drug products you produce, as well as, third party testing conducted on 10 of the (b)(4) lots offered for importation. The third party testing conducted on “lot 0720”, the same as that tested by FDA, identified variability in the formulation. Specifically, the first sample from the upper layers of the bottle demonstrated subpotency (54%) and upon additional mixing of the sampe bottle you obtained a result of 68%. Your gel formulation does not appear to have uniform character and quality. Furthermore, you acknowledged that Simex released at least two of the (b)(4) lots to the U.S. market without performing finished product testing, a violation of 21 CFR 211.165.\n\nIn addition to the third party testing results, you offered details on the in-house testing that you are now using to test your drug products. The method of in-house testing uses a refractometer device that is unsuitable for the testing of finished hand sanitizers that contain materials other than ethanol and water in their matrix. Furthermore, you state that due to the “antiseptic nature of the product” there is no testing performed for objectionable microbiological contamination. Failure to adequately test prior to release or assure that the drug products have the identity, strength, quality and purity they purport or are represented to possess are violations of CGMP requirements. See 21 CFR 211.165 and 211.100.\n\nUltimately, you committed to recall all hand sanitizer drug products manufactured by your firm within expiration. You issued a voluntary recall on November 25, 2020. On November 10, 2020, FDA notified the public of the subpotency of your hand sanitizer drugs products at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nIn response to this letter provide the following:\n\n• Your plans to reformulate your drug product.\n\n• A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing including both production and packaging operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\n\n• A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\n• A list of appropriate chemical and microbial test methods and specifications used to analyze each lot of your components and drug product before making a lot disposition decision, and the associated written procedures.\n\nThe subpotency of active ingredient ethanol in this drug product declared as manufactured at your facility and the documents you provided demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the Act.2\n\nUnapproved New Drug and Misbranding Violations\n\nHEALTH & HAND GEL HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the HEALTH & HAND GEL HAND SANITIZER product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“HAND SANITIZER . . . Drug Facts . . . Purpose . . . Antimicrobial . . . Use(s) . . . Helps reduce bacteria on the skin that could cause diseases . . . Directions ∙ Place enough product in the palm of your hands to thoroughly cover your hands. ∙ Rub hands together briskly until product is completely absorbed and hands are dry.” (product label)\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your HEALTH & HAND GEL HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOver the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, HEALTH & HAND GEL HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act, as added by the CARES Act, for marketing without an approved application under section 505.\n\nAccording to the product label, HEALTH & HAND GEL HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 70%. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that HEALTH & HAND GEL HAND SANITIZER contains ethanol in a concentration that is less than the 70% stated on its product label and less than the amount of ethanol described in the 1994 TFM.3 Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.4\n\nAdditionally, this drug product, HEALTH & HAND GEL HAND SANITIZER, is misbranded under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee).\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, HEALTH & HAND GEL HAND SANITIZER is labeled to contain ethyl alcohol 70%. However, FDA laboratory analyses of a batch of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label. Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol) in the product causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because HEALTH & HAND GEL HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements, if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on November 17, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practice within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nAfter you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nIdentify your response with FEI 3016774460 and ATTN: Tamara Ely.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent\n\nAldo Martinez\n\n1600 University Blvd\n\nBrownsville, Texas 78520\n\ncontrol@regulab.us\n\n_________________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on August 7, 2020. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of ethanol in hand sanitizer products manufactured at your facility, a review of your drug product labeling further indicates that the product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n3 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n4 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because HEALTH & HAND GEL HAND SANITIZER is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Simex Logistics S.A. de C.V.","simex-logistics-sa-de-cv-610529-01282021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsimex-logistics-sa-de-cv-610529-01282021","2026-10-26T08:09:57.749066+00:00","2021-02-09","610529","Mr. Jose Ambrosio Rodriguez","2026-08-20T03:24:43.516+00:00","2021-01-28",{"id":69,"raw":70,"subject":12,"body_html":74,"body_text":75,"firm_name":76,"letter_id":77,"created_at":78,"fei_number":19,"letter_url":79,"updated_at":80,"action_type":22,"case_status":23,"posted_date":81,"marcs_cms_no":82,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":83,"body_fetched_at":84,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":85,"medical_device_id":19,"response_letter_date":19},2582,[71,72,73,37,38,13,13,13],"\u003Ctime datetime=\"2022-07-12T13:20:00Z\">07\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-27T04:00:00Z\">06\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoticias-mexico-hoy-grupo-multimedia-sa-de-cv-609658-06272022\">Noticias Mexico Hoy Grupo Multimedia, S.A. de C.V.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Francisco Cervantes\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Noticias Mexico Hoy Grupo Multimedia, S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Privada Rio Atoyac No. 23\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Colonia Rancho Colorado\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>72040\u003C\u002Fspan> \u003Cspan>Puebla\u003C\u002Fspan>, \u003Cspan>Pue.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-22-19\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 27, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Cervantes:\u003C\u002Fp>\n\n\u003Cp>Your firm was recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a drug product manufactured at your facility: Medical MARY CLEAN HAND Sanitizers, a consumer antiseptic rub (also referred to as consumer hand sanitizers) declared as manufactured by Noticias Mexico Hoy Grupo Multimedia SA de CV, FEI 3016821022, at Privada Rio Atoyac No. 23 Puebla, Mexico. Following an attempted import into the United States, Medical MARY CLEAN HAND Sanitizers was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of a batch of this product detained at the border demonstrated that this drug product is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, the product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, Medical MARY CLEAN HAND Sanitizers is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (x) and (ee). Introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your drug product, Medical Mary Clean Hand Sanitizers is labeled to contain 75% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that your Medical Mary Clean Hand Sanitizers contained an average of 0.34% ethanol and 78% of methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient of ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethanol) substitute are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>We were unable to contact your US Agent. On August 6, 2020, FDA notified the public of methanol contamination of your hand sanitizer at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>FDA held a teleconference with Medical Mary LLC, a distributor of your products on August 10, 2020. We recommended they consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. Your distributor agreed to recall all Medical Mary hand sanitizer drug products. However, to date, neither your firm nor your distributor (Medical Mary LLC) have taken market action.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed investigation into how Medical Mary Clean Hand Sanitizers, declared as manufactured at your facility, and labeled as containing ethanol, were substituted in part or in whole with methanol.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fp>\n\n\u003Cp>The substitution and contamination with methanol in a hand sanitizer drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility does not appear to be functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Medical MARY CLEAN HAND Sanitizers is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the Medical MARY CLEAN HAND Sanitizers product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“ANTI-BACTERIAL. . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . \u003Cstrong>Use\u003C\u002Fstrong> Hand Sanitizer to help reduce bacteria on the skin . . . \u003Cstrong>Directions\u003C\u002Fstrong> – Put enough product in your palm to cover hands and rub hands together briskly until dry.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Medical MARY CLEAN HAND Sanitizers drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol, and isopropyl alcohol) were classified as Category III for use as consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified in such a TFM as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, Medical MARY CLEAN HAND Sanitizers does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, Medical MARY CLEAN HAND Sanitizers purportedly contains the active ingredient ethyl alcohol 75% v\u002Fv. However, as previously discussed, FDA laboratory analysis revealed that a sample of Medical MARY CLEAN HAND Sanitizers contains a concentration of ethanol that is far less than the 75% v\u002Fv declared on the label. Such a product does not conform to the TFM or other applicable requirements.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analysis also revealed that a sample of Medical MARY CLEAN HAND Sanitizers contains a significant concentration of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, Medical MARY CLEAN HAND Sanitizers, is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (x), and (ee). It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, Medical MARY CLEAN HAND Sanitizers is labeled to contain ethyl alcohol 75% v\u002Fv. However, FDA laboratory analysis of a batch of this product demonstrates that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label, and it contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol) and the failure of the product label to disclose the presence of methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of this product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A). Furthermore, this product is misbranded under section 502(x) of the FD&amp;C Act, 21 U.S.C. 352(x), because the product label fails to disclose a domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because Medical MARY CLEAN HAND Sanitizers is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant, qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 21, 2020. Your drug products may be subject to detention without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016821022 and ATTN: Carla Norris.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nCesar Lopez\u003Cbr>\n3942 West 11th Place\u003Cbr>\nIngelwood, CA 90303\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nConsignee\u003Cbr>\nMedical Mary LLC\u003Cbr>\n3079 Baldwin Rd.\u003Cbr>\nLake Orion, MI 48359-1028\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nCAF Medical Solutions Inc.\u003Cbr>\n4900 W Expressway 83 STE 240\u003Cbr>\nMcallen TX, 78501\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that “Medical MARY CLEAN HAND Sanitizers” also does not conform to any temporary policy FDA had implemented during the public health emergency. In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 public health emergency (PHE). On December 31, 2021, these guidance’s were withdrawn, and firms must have ceased distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies. See 86 FR 56960, October 13, 2021.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Francisco Cervantes\n\nRecipient Title\n\nChief Executive Officer\n\nNoticias Mexico Hoy Grupo Multimedia, S.A. de C.V.\n\nPrivada Rio Atoyac No. 23\n\nColonia Rancho Colorado\n\n72040 Puebla, Pue.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-22-19\n\nJune 27, 2022\n\nDear Mr. Cervantes:\n\nYour firm was recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a drug product manufactured at your facility: Medical MARY CLEAN HAND Sanitizers, a consumer antiseptic rub (also referred to as consumer hand sanitizers) declared as manufactured by Noticias Mexico Hoy Grupo Multimedia SA de CV, FEI 3016821022, at Privada Rio Atoyac No. 23 Puebla, Mexico. Following an attempted import into the United States, Medical MARY CLEAN HAND Sanitizers was detained and refused admission at the border.\n\nThe results of FDA laboratory testing of a batch of this product detained at the border demonstrated that this drug product is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, the product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, Medical MARY CLEAN HAND Sanitizers is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (x) and (ee). Introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nYour drug product, Medical Mary Clean Hand Sanitizers is labeled to contain 75% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that your Medical Mary Clean Hand Sanitizers contained an average of 0.34% ethanol and 78% of methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient of ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethanol) substitute are most at risk for methanol poisoning.\n\nWe were unable to contact your US Agent. On August 6, 2020, FDA notified the public of methanol contamination of your hand sanitizer at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nFDA held a teleconference with Medical Mary LLC, a distributor of your products on August 10, 2020. We recommended they consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. Your distributor agreed to recall all Medical Mary hand sanitizer drug products. However, to date, neither your firm nor your distributor (Medical Mary LLC) have taken market action.\n\nIn response to this letter provide the following:\n\n• A detailed investigation into how Medical Mary Clean Hand Sanitizers, declared as manufactured at your facility, and labeled as containing ethanol, were substituted in part or in whole with methanol.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\nThe substitution and contamination with methanol in a hand sanitizer drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility does not appear to be functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the Act.\n\nUnapproved New Drug and Misbranding Violations\n\nMedical MARY CLEAN HAND Sanitizers is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended as a consumer antiseptic rub.\n\nExamples of claims observed on the Medical MARY CLEAN HAND Sanitizers product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“ANTI-BACTERIAL. . . Drug Facts . . . Use Hand Sanitizer to help reduce bacteria on the skin . . . Directions – Put enough product in your palm to cover hands and rub hands together briskly until dry.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Medical MARY CLEAN HAND Sanitizers drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol, and isopropyl alcohol) were classified as Category III for use as consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified in such a TFM as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, Medical MARY CLEAN HAND Sanitizers does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, Medical MARY CLEAN HAND Sanitizers purportedly contains the active ingredient ethyl alcohol 75% v\u002Fv. However, as previously discussed, FDA laboratory analysis revealed that a sample of Medical MARY CLEAN HAND Sanitizers contains a concentration of ethanol that is far less than the 75% v\u002Fv declared on the label. Such a product does not conform to the TFM or other applicable requirements.1\n\nFDA laboratory analysis also revealed that a sample of Medical MARY CLEAN HAND Sanitizers contains a significant concentration of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.2,3\n\nAdditionally, this methanol-containing drug product, Medical MARY CLEAN HAND Sanitizers, is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (x), and (ee). It is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, Medical MARY CLEAN HAND Sanitizers is labeled to contain ethyl alcohol 75% v\u002Fv. However, FDA laboratory analysis of a batch of this product demonstrates that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label, and it contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol) and the failure of the product label to disclose the presence of methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of this product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A). Furthermore, this product is misbranded under section 502(x) of the FD&C Act, 21 U.S.C. 352(x), because the product label fails to disclose a domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because Medical MARY CLEAN HAND Sanitizers is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant, qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 21, 2020. Your drug products may be subject to detention without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\n\nIdentify your response with FEI 3016821022 and ATTN: Carla Norris.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent\n\nCesar Lopez\n\n3942 West 11th Place\n\nIngelwood, CA 90303\n\nCC:\n\nConsignee\n\nMedical Mary LLC\n\n3079 Baldwin Rd.\n\nLake Orion, MI 48359-1028\n\nCC:\n\nCAF Medical Solutions Inc.\n\n4900 W Expressway 83 STE 240\n\nMcallen TX, 78501\n\n____________________________\n\n1 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n2 We note that “Medical MARY CLEAN HAND Sanitizers” also does not conform to any temporary policy FDA had implemented during the public health emergency. In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 public health emergency (PHE). On December 31, 2021, these guidance’s were withdrawn, and firms must have ceased distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies. See 86 FR 56960, October 13, 2021.\n\n3 An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Noticias Mexico Hoy Grupo Multimedia, S.A. de C.V.","noticias-mexico-hoy-grupo-multimedia-sa-de-cv-609658-06272022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnoticias-mexico-hoy-grupo-multimedia-sa-de-cv-609658-06272022","2026-10-26T08:09:35.118776+00:00","2022-07-12","609658","Mr. Francisco Cervantes","2026-08-20T01:46:39.068+00:00","2022-06-27",{"id":87,"raw":88,"subject":92,"body_html":93,"body_text":94,"firm_name":95,"letter_id":96,"created_at":18,"fei_number":19,"letter_url":97,"updated_at":98,"action_type":22,"case_status":23,"posted_date":99,"marcs_cms_no":100,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":101,"body_fetched_at":102,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":103,"medical_device_id":19,"response_letter_date":19},3122,[89,90,91,37,92,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-29T04:00:00Z\">09\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthy-foods-nutrition-lab-de-mexico-sa-de-cv-609608-09292021\">Healthy Foods &amp; Nutrition Lab de Mexico S.A. de C.V.\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Juan Pablo Maza Gomez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Healthy Foods &amp; Nutrition Lab de Mexico S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Calle Curtidores No. 38 Zona Industrial Xhala\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>54714\u003C\u002Fspan> \u003Cspan>Cuautitlan\u003C\u002Fspan>, \u003Cspan>Méx.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-21-62\u003C\u002Fp>\n\n\u003Cp>September 29, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Gomez:\u003C\u002Fp>\n\n\u003Cp>Your firm was registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION. This drug product was labeled as manufactured at your facility, Healthy Foods and Nutrition Lab de Mexico, S.A. de C.V., FEI 3015851305, at Calle Curtidores Num. 38 Zona Industrial Xhala, Cuautitlan. Following an attempt to import HF&amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(a), (x), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a), (x), and (ee). Introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>HF&amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION, labeled as manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of only 13% v\u002Fv ethanol. This hand sanitizer drug product is adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its labeling.\u003C\u002Fp>\n\n\u003Cp>CDC recommends\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>On July 29, 2020, FDA held a teleconference with you and Registrar Corporation, your registered U.S. Agent at the time. We recommended that you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On July 30, 2020, FDA notified the public of the subpotency of your hand sanitizer drug products at the following website:&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>During the July 29, 2020 teleconference, you stated that the subpotent batch that was distributed to the U.S. was an isolated incident. However, you provided subsequent correspondence dated August 7, 2020, acknowledging that you had other subpotent batches manufactured by your firm. However, as of the date of this letter you have yet to take market action based on FDA’s recommendation.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide:\u003Cbr>\n• A detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 70% ethanol, in fact contained an average of 13% ethanol.\u003Cbr>\n• A list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003Cbr>\n• A complete, comprehensive, independent assessment of your quality unit, including laboratory oversight, and procedures related to release decisions.\u003Cbr>\n• In your August 7, 2020 correspondence, you provided information describing some of your laboratory procedures. . Provide a complete comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• In your August 7, 2020 correspondence, you indicated a temporary personnel issue led to one lot of subpotent drug product shipped to the U.S. and you were able to catch other lots that were subpotent. The fact that you manufactured other subpotent lots calls into question your process validation as required under 21 CFR 211.100(a). Provide process validation procedures and protocols for all drug products you plan to ship to the U.S. in the future.\u003C\u002Fp>\n\n\u003Cp>The subpotency of hand sanitizer drug products labeled as manufactured in your facility demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“Antiseptic Hand Rub . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . \u003Cstrong>Uses(s)\u003C\u002Fstrong> Hand sanitizer to help reduce bacteria that potentially can cause disease . . . \u003Cstrong>Directions\u003C\u002Fstrong> . . . Place enough product on hands to cover all surfaces. Rub hands together until dry.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use as consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act, addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION purportedly contains the active ingredient ethyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analysis of a batch of this product detained at the border demonstrated that HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION contains ethanol in a concentration that is less than the 70% stated on its product label and less than the amount of ethanol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is labeled to contain ethanol 70% v\u002Fv. However, FDA laboratory analysis of a batch of this product demonstrate that the product contains a concentration of ethanol that is far less than that stated on its product label. Thus, the misleading representations of the concentration of the active ingredient ethanol on the HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION labeling cause this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>Furthermore, this product is misbranded under section 502(x) of the FD&amp;C Act, 21 U.S.C. 352(x), because the product label fails to disclose a domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 13, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3015851305 and ATTN: Towanda Terrell.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\n\u003Cbr>\nCC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nRegistrar Corp\u003Cbr>\nDavid Lennarz\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, VA 23666\u003Cbr>\nUSA\u003C\u002Fp>\n\n\u003Cp>\u003Cb>(b)(6)\u003C\u002Fb>\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\">https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of the hand sanitizer product labeled as manufactured at your facility, a review of the purported formulations on the drug product’s labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of “60 to 95 percent by volume in an aqueous solution denatured according to Bureau of Alcohol, Tobacco and Fireamrs regulations in 21 CFR part 20.” 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs,&nbsp;and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem>. Because HF &amp; NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003Cbr>\n\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Juan Pablo Maza Gomez\n\nRecipient Title\n\nCEO\n\nHealthy Foods & Nutrition Lab de Mexico S.A. de C.V.\n\nCalle Curtidores No. 38 Zona Industrial Xhala\n\n54714 Cuautitlan, Méx.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-62\n\nSeptember 29, 2021\n\nDear Mr. Gomez:\n\nYour firm was registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION. This drug product was labeled as manufactured at your facility, Healthy Foods and Nutrition Lab de Mexico, S.A. de C.V., FEI 3015851305, at Calle Curtidores Num. 38 Zona Industrial Xhala, Cuautitlan. Following an attempt to import HF& NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(a), (x), and (ee) of the FD&C Act, 21 U.S.C. 352(a), (x), and (ee). Introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nHF& NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION, labeled as manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of only 13% v\u002Fv ethanol. This hand sanitizer drug product is adulterated under section 501(c) of the FD&C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its labeling.\n\nCDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOn July 29, 2020, FDA held a teleconference with you and Registrar Corporation, your registered U.S. Agent at the time. We recommended that you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. On July 30, 2020, FDA notified the public of the subpotency of your hand sanitizer drug products at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nDuring the July 29, 2020 teleconference, you stated that the subpotent batch that was distributed to the U.S. was an isolated incident. However, you provided subsequent correspondence dated August 7, 2020, acknowledging that you had other subpotent batches manufactured by your firm. However, as of the date of this letter you have yet to take market action based on FDA’s recommendation.\n\nIn response to this letter provide:\n\n• A detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 70% ethanol, in fact contained an average of 13% ethanol.\n\n• A list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\n• A complete, comprehensive, independent assessment of your quality unit, including laboratory oversight, and procedures related to release decisions.\n\n• In your August 7, 2020 correspondence, you provided information describing some of your laboratory procedures. . Provide a complete comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• In your August 7, 2020 correspondence, you indicated a temporary personnel issue led to one lot of subpotent drug product shipped to the U.S. and you were able to catch other lots that were subpotent. The fact that you manufactured other subpotent lots calls into question your process validation as required under 21 CFR 211.100(a). Provide process validation procedures and protocols for all drug products you plan to ship to the U.S. in the future.\n\nThe subpotency of hand sanitizer drug products labeled as manufactured in your facility demonstrate that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nUnapproved New Drug and Misbranding Violations\n\nHF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended as a consumer topical antiseptic.\n\nExamples of claims observed on the HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Antiseptic Hand Rub . . . Drug Facts . . . Uses(s) Hand sanitizer to help reduce bacteria that potentially can cause disease . . . Directions . . . Place enough product on hands to cover all surfaces. Rub hands together until dry.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use as consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act, addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION purportedly contains the active ingredient ethyl alcohol 70% v\u002Fv. However, as previously discussed, FDA laboratory analysis of a batch of this product detained at the border demonstrated that HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION contains ethanol in a concentration that is less than the 70% stated on its product label and less than the amount of ethanol described in the 1994 TFM.3 Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.4\n\nAdditionally, this hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is labeled to contain ethanol 70% v\u002Fv. However, FDA laboratory analysis of a batch of this product demonstrate that the product contains a concentration of ethanol that is far less than that stated on its product label. Thus, the misleading representations of the concentration of the active ingredient ethanol on the HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION labeling cause this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nFurthermore, this product is misbranded under section 502(x) of the FD&C Act, 21 U.S.C. 352(x), because the product label fails to disclose a domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 13, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3015851305 and ATTN: Towanda Terrell.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent\n\nRegistrar Corp\n\nDavid Lennarz\n\n144 Research Drive\n\nHampton, VA 23666\n\nUSA\n\n(b)(6)\n\n_____________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of the hand sanitizer product labeled as manufactured at your facility, a review of the purported formulations on the drug product’s labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n3 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of “60 to 95 percent by volume in an aqueous solution denatured according to Bureau of Alcohol, Tobacco and Fireamrs regulations in 21 CFR part 20.” 59 FR 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n4 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because HF & NLab VERIO HEALTHCARE ALCOHOL ANTISEPTIC TOPICAL SOLUTION is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n4 The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.","Healthy Foods & Nutrition Lab de Mexico S.A. de C.V.","healthy-foods-nutrition-lab-de-mexico-sa-de-cv-609608-09292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthy-foods-nutrition-lab-de-mexico-sa-de-cv-609608-09292021","2026-10-26T08:08:53.875725+00:00","2021-10-05","609608","Mr. Juan Pablo Maza Gomez","2026-08-20T02:34:43.493+00:00","2021-09-29",5,{"510k":106,"classification":107,"enforcement":108,"event":109,"event_backfill":110,"pma":111,"warning_letter":112},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]